Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
13 hedge funds and large institutions have $14.2M invested in Anebulo Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.14% more ownership
Funds ownership: 28.18% → 28.32% (+0.14%)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
29% less capital invested
Capital invested by funds: $20M → $14.2M (-$5.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.63K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$348 |
| 4 |
BlackRock
New York
|
+$307 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$2.13K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.29K |
| 3 |
JP Morgan Chase
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $10.4M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.24M | -$2.13K | -1,000 | -0.2% |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $986K | – | – | – |
|
4
Morgan Stanley
New York
| $770K | – | – | – |
|
|
IC
5
Ikarian Capital
Dallas,
Texas
| $305K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $297K | +$348 | +163 | +0.1% |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| $169K | +$77.8K | +36,482 | +71% |
|
|
BFM
8
Boothbay Fund Management
New York
| $36.6K | – | – | – |
|
|
9
BlackRock
New York
| $7.54K | +$307 | +144 | +4% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $5.2K | -$1.29K | -606 | -18% |
|
|
11
UBS Group
Zurich,
Switzerland
| $1.47K | +$1.63K | +763 | New |
|
|
12
Bank of America
Charlotte,
North Carolina
| $147 | +$23 | +11 | +17% |
|
|
13
JP Morgan Chase
New York
| $17 | -$2 | -1 | -10% |
|
ANEB Hedge Fund Activity: Q3 2024 in Review
13 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q3 2024, worth a combined $14.2M — down 29% from $20M a quarter earlier.
Fund positioning in ANEB was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $77.8K. The largest seller was LVW Advisors, cutting an estimated $2.13K.
- 13 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $14.2M of Anebulo Pharmaceuticals stock for Q3 2024, down 29% quarter-over-quarter.
- 1 fund opened new Anebulo Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest Anebulo Pharmaceuticals buyer in Q3 2024 was Geode Capital Management, an estimated $77.8K added.
- The largest Anebulo Pharmaceuticals seller in Q3 2024 was LVW Advisors, an estimated $2.13K sold.
Based on aggregated 13F filings for Q3 2024.